Other News To Note
Friday, December 10, 2010
PharmAthene Inc., of Annapolis, Md., said the FDA lifted the partial clinical hold imposed last year on Valortim, a fully human anti-toxin monoclonal antibody being developed for the prevention and treatment of inhalational anthrax, clearing the company to move forward with a Phase I intravenous dose-escalation study in the coming weeks, which Roth Capital Partners analyst Joseph Pantginis called an "encouraging event" for the company.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.